Physician profile
Eli Noah Jackson
NPI 1316583461
$3,178.98
in general payments reported to CMS, 2019-2025
26 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.14 · 2023: $1,176 · 2024: $1,720 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $598.16 | 2023-2025 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $289.96 | 2023-2025 | Myrisk, Prolaris |
| Abbvie INC. | $285.73 | 2023-2024 | |
| Verity Pharmaceuticals INC. | $262.17 | 2023-2025 | Trelstar |
| Dendreon Pharmaceuticals LLC | $249.72 | 2023-2024 | Provenge |
| Janssen Biotech, INC. | $213.92 | 2023-2024 | Erleada, Akeega |
| Boston Scientific Corporation | $163.97 | 2023-2024 | Rezum Generator, Ams 700, Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $146.56 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $133.10 | 2024 | Adstiladrin |
| Pfizer INC. | $130.02 | 2023-2025 | |
| Urogen Pharma, INC. | $120.20 | 2023-2024 | Jelmyto |
| Astellas Pharma US INC | $91.63 | 2023-2024 | Xtandi |
| Procept Biorobotics Corporation | $87.50 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Tolmar, INC. | $69.48 | 2023-2025 | Jatenzo, Eligard |
| Blue Earth Diagnostics | $54.74 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.77 | 2024-2025 | Lynparza, Keytruda |
| Olympus America INC. | $41.86 | 2023 | Itind System |
| Antares Pharma, INC. | $41.50 | 2024 | Xyosted |
| Endo Pharmaceuticals INC. | $33.83 | 2023-2024 | Xiaflex |
| Medtronic, INC. | $19.87 | 2023 | Interstim |
| Endo USA, INC. | $18.51 | 2024 | Xiaflex |
| Teleflex LLC | $18.26 | 2023 | Urolift |
| Coloplast Corp | $17.73 | 2024 | |
| Halozyme INC | $17.06 | 2023 | |
| Sagent Pharmaceuticals | $13.59 | 2023 | Glydo |
| Radius Health, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.